share_log

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Gibson Christopher

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Gibson Christopher

Recursion Pharmaceuticals | 4：持股變動聲明-高管 Gibson Christopher
美股SEC公告 ·  08/31 04:28
牛牛AI助理已提取核心訊息
Christopher Gibson, CEO of Recursion Pharmaceuticals, has engaged in a stock purchase transaction for the company's shares. On August 30, 2024, Gibson acquired 5,000 shares of Recursion Pharmaceuticals' Class A Common Stock at a price of $2.48 per share. Following this transaction, Gibson's direct holdings in the company increased to a total of 762,656 shares. The transaction is currently reported as in progress.
Christopher Gibson, CEO of Recursion Pharmaceuticals, has engaged in a stock purchase transaction for the company's shares. On August 30, 2024, Gibson acquired 5,000 shares of Recursion Pharmaceuticals' Class A Common Stock at a price of $2.48 per share. Following this transaction, Gibson's direct holdings in the company increased to a total of 762,656 shares. The transaction is currently reported as in progress.
Recursion Pharmaceuticals的CEO Christopher Gibson已經參與了公司股票購買交易。2024年8月30日，Gibson以每股2.48美元的價格收購了5,000股Recursion Pharmaceuticals的A類普通股。在這次交易之後，Gibson在公司的直接持股增加到了總共762,656股。該交易目前被報告爲正在進行中。
Recursion Pharmaceuticals的CEO Christopher Gibson已經參與了公司股票購買交易。2024年8月30日，Gibson以每股2.48美元的價格收購了5,000股Recursion Pharmaceuticals的A類普通股。在這次交易之後，Gibson在公司的直接持股增加到了總共762,656股。該交易目前被報告爲正在進行中。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間